An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study-Reference-Cited by-同舟云学术

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

Published:2013-05 Issue:5 Volume:12 Page:435-442
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Miller Timothy M,Pestronk Alan,David William,Rothstein Jeffrey,Simpson Ericka,Appel Stanley H,Andres Patricia L,Mahoney Katy,Allred Peggy,Alexander Katie,Ostrow Lyle W,Schoenfeld David,Macklin Eric A,Norris Daniel A,Manousakis Georgios,Crisp Matthew,Smith Richard,Bennett C Frank,Bishop Kathie M,Cudkowicz Merit E

Funder

National Institute of Neurological Disorders and Stroke (NIH)

Washington University Institute of Clinical and Translational Sciences

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference22 articles.

1. Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease;Bras;Nat Rev Neurosci,2012

2. Gene-targeted therapies for the central nervous system;Miller;Arch Neurol,2008

3. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform;Bennett;Annu Rev Pharmacol Toxicol,2010

4. Antisense oligonucleotide therapy for neurodegenerative disease;Smith;J Clin Invest,2006

5. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis;Kordasiewicz;Neuron,2012

Cited by 537 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Neuroimmunomodulation Frontier: Pioneering Approaches and Promising Horizons—A Comprehensive Review;International Journal of Molecular Sciences;2024-09-07

2. Gene therapy for polygenic or complex diseases;Biomarker Research;2024-09-04

3. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs;Molecular Therapy - Nucleic Acids;2024-09

4. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside;Cancers;2024-08-23

5. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier;Science Translational Medicine;2024-08-14